血吸虫病候选疫苗临床研究进展

Research progress on clinical trials of schistosomiasis vaccine candidates

血吸虫病是由血吸虫寄生而引起的人兽共患寄生虫病,严重危害人类健康,影响社会经济发展。血吸虫病疫苗一直备受关注,有助于降低对吡喹酮的过度依赖,推进控制和消除血吸虫病目标的实现。目前虽然尚无商业化的血吸虫病疫苗,但谷胱甘肽S-转移酶、脂肪酸结合蛋白、四跨膜蛋白-2和钙蛋白酶大亚基等4种候选疫苗已进入不同阶段的人体临床试验。本文对4种血吸虫病候选疫苗的临床研究进展、面临的挑战进行综述,以期为我国血吸虫病疫苗与其他蠕虫病疫苗的研发提供线索和借鉴。

Schistosomiasis is a wide-spread parasitic zoonosis caused by Schistosoma, which seriously harms human health and affects socioeconomic development worldwide. Schistosomiasis vaccines have attracted much attention as they will contribute not only to reducing the over-reliance on praziquantel for the treatment of this disease but also to achieving the goal of disease control and elimination. There have been no schistosomiasis vaccines available until now;however, four schistosomiasis vaccine candidates, glutathione S-transferase, fatty acid binding protein, tetraspanin-2 and calpain, have entered human clinical trials. This paper reviewed the clinical research progress and challenges of the four schistosomiasis vaccine candidates to provide insights into developing vaccines for schistosomia-sis and other helminthiases in China.